Discover the exciting results of the first-in-human trial of AMP-303 from Amplifica
Amplifica, a San Diego-based clinical-stage biopharmaceutical company, has announced encouraging results from its first-in-human trial of AMP-303, an intradermal injection therapy for androgenic alopecia (AGA). The company is also developing other AGA treatments, including AMP-203 (osteopontin) and AMP-601 (SCUBE3).
What is AMP-303?
We first covered AMP-303 when Amplifica announced the trial’s initiation last year. While detailed information about the formulation remains limited, it is known that it is a proprietary product designed for direct injection into the scalp to treat AGA.
Trial Overview and Results
The study enrolled male participants aged 18-45 with varying durations of hair loss:
- Recent onset: 3-5 years
- Long-standing hair loss: Over 10 years
Each participant received AMP-303 injections on one side of the scalp and a placebo on the other.
Key Findings:
- At 60 days post-treatment, a statistically significant number of participants saw over 15% non-vellus hair growth compared to the placebo.
- At 150 days, participants continued to show improvements, with over 10% hair growth relative to the placebo.
- Adverse events were mild, with no severe events reported.
Conclusion
Although the results appear promising, it is difficult to fully assess their clinical significance without access to raw data or visual evidence of hair regrowth. We hope Amplifica will release more comprehensive data, including images, in the future to give a clearer picture of the product’s effectiveness.
SHOP FOR HAIR LOSS TREATMENTS
